Aktienanalyse zu Kestra Medical Technologies Ltd (KMTS)KMTSKestra Medical Technologies Ltd

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies (KMTS) is currently not a strong buy due to its low RSI of 23.147, indicating oversold conditions, and a recent 5-day price drop of 5.00%. However, the company has shown significant revenue growth, with Q2 2026 revenue at $22,565,000, a 63% year-over-year increase in prescription volume, and a positive analyst outlook with a price target of $30 from JPMorgan. The main risk is its negative net income, which was -$38,835,000 in Q4 2026, indicating ongoing financial challenges.